Contact

Prediction of cognition in Parkinson's disease 10 years after onset

Cognitive decline is one of the most debilitating manifestations of disease progression in Parkinson's disease and is a key determinant of a patient's quality of life and independence.1 The ability to predict and to manage this complication is highly relevant for recruitment into and stratification of clinical trials, particularly those designed to slow disease progression and to prevent dementia. Although a multitude of drugs for Parkinson's disease is available to improve motor aspects of the disease, these do not have a major effect on cognitive decline.

The authors of a study published in The Lancet Neurology aimed to develop a clinical–genetic score to predict global cognitive impairment in patients with the disease. This international study involving clinicians from AP-HP, Inserm, UPMC at ICM was conducted using 9 cohorts gathering 3200 patients. The resulting predictive algorithm provides a potential test for future cognitive health or impairment in patients with Parkinson's disease. This model could improve trials of cognitive interventions and inform on prognosis.

In France, the DIG-PD cohort, coordinated by Pr Jean-Christophe Corvol at ICM, followed more than 400 patients for 6 years.

NeurATRIS at RegMed '17 (July 7, Paris)

NeurATRIS will be participating to RegMed Europe on July 7, 2017, in Paris, the first european matchmaking event on regenerative medicine.

Participants will get information about the ongoing regenerative medicine challenges and topics, learn about the major European ecosystems, get the chance to present their innovative projects, and meet the European actors in their field to build international partnerships.

Main topics:

  • Cell therapy
  • Gene therapy
  • Biomaterials
  • Tissue engineering

You will be able to meet our business developper, Ali AIT-IKHLEF, who can tell you more about NeurATRIS assets to work alongside in your translational projects in the Neuroscience field for the characterization of neurodegenerative diseases.

Do not hesitate to This email address is being protected from spambots. You need JavaScript enabled to view it.us to set up a meeting.

NeurATRIS

NEURATRIS AT "MEDECINE TRANSLATIONNELLE" (13th June, Paris)

NeurATRIS is pleased to announce that we will be participating to « Médecine Translationnelle au service de l’innovation Thérapeutique : Enjeux, Besoins et Opportunités » (13th June, Paris)

The goal of this day is to provide an overview of translational medicine platforms of key account (academic and pharmaceutical industries) in order to understand how they work, their needs and their roles in the value chain of discovery and development of therapeutic solutions.

This is a unique opportunity to hear P. HANTRAYE, NeurATRIS director, and learn more about NeurATRIS assets to work alongside in your translational projects in the Neuroscience field for the characterization of neurodegenerative diseases.

Do not hesitate to This email address is being protected from spambots. You need JavaScript enabled to view it.">contact us to set up a meeting.

 

NeurATRIS

World Multiple Sclerosis day, May 31, 2017

On the occasion of World Multiple Sclerosis day, on May 31st, the french magazine "Sciences et Avenir" dedicates an article to promising recent work from Catherine Lubetzki's team at the Brain and Spine Institute (ICM) in Paris.

Several studies from the team have shown the importance of the remyelination process in patient health state. In its most frequent form, multiple sclerosis is indeed charaterized by inflammatory bursts in the central nervous system (brain and spine), followed by respite periods during which myelin is partially rebuilt.

New imaging techniques developped at ICM, more precise than MRI, allowed to show that this reparation "potential" differs a lot among patients : by injecting a specific tracer that fixes on myelin, before performing a PET scan, the degree of myelin degradation can be measured.

You can find the complete article (in French) on the magazine website.